Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 14/20 | 0.85 |
| ▸ | MEN1 | O00255 | 13/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 6/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.85 |
| ▸ | POLB | P06746 | 6/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.69 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.66 |
| ▸ | ALPL | P05186 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 2/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | ALPG | P10696 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13345901 | 0.90 | KMT2A (0.85) | KMT2AMEN1MAPK1MAPTKDM4E | |
| SCHEMBL13888257 | 0.90 | MEN1 (1.00) | KMT2AMEN1MAPK1MAPTKDM4E | |
| SCHEMBL13345887 | 0.80 | MAPT (0.84) | KMT2AMEN1MAPK1MAPTKDM4E | |
| SCHEMBL10492165 | 0.77 | PTPN12 (0.77) | KMT2AMEN1POLB | |
| SCHEMBL10492163 | 0.77 | PTPN12 (0.77) | KMT2AMEN1POLB | |
| SCHEMBL5992046 | 0.77 | MEN1 (1.00) | KMT2AMEN1MAPK1MAPTKDM4E | |
| SCHEMBL12008603 | 0.75 | KMT2A (0.79) | KMT2AMEN1MAPK1MAPTKDM4E | |
| SCHEMBL12010971 | 0.74 | MEN1 (1.00) | KMT2AMEN1MAPK1MAPTL3MBTL1 | |
| SCHEMBL17319563 | 0.73 | KMT2A (0.83) | KMT2AMEN1MAPK1MAPTL3MBTL1 | |
| SCHEMBL15702369 | 0.72 | KMT2A (0.80) | KMT2AMEN1MAPK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | KMT2A 3993/4885MEN1 2560/4885MAPK1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.